WASHINGTON (AP) — Popular weight loss and diabetes drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated directly between the government and ...
Pfizer’s top-selling breast cancer drug Ibrance also on list Drugmakers plan to ask Trump administration to pause talks The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters ...
The K-9 helped find the shooting suspect hiding under trash in a dumpster, authorities said. (KHOU, US Marshall photos of K9) ...
Following the poorer-than-hoped performance of CagriSema last month, Novo Nordisk needed an emphatic clinical success with its high-dose version of Wegovy. The … ...
Ashley Davidson, vice president of sponsor and tech strategy at Advarra, discusses her outlook for this year’s edition of the SCOPE summit. The global market for clinical trials is expected to grow to ...
Semaglutide 2.4 mg is marketed under the brand name Wegovy. STEP UP is a 72-week efficacy and safety trial investigating subcutaneous semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo ...
Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for Medicare price negotiations for 2027, the government said on Friday ...
(CNN) — Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to the next round of Medicare price negotiations ...
(CNN) — Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to the next round of Medicare price negotiations, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback